Allied Biotech Corporation
Allied Biotech Corporation manufactures and sells carotenoids worldwide. Its products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharm… Read more
Allied Biotech Corporation (1780) - Total Assets
Latest total assets as of September 2025: NT$2.30 Billion TWD
Based on the latest financial reports, Allied Biotech Corporation (1780) holds total assets worth NT$2.30 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Allied Biotech Corporation - Total Assets Trend (2019–2024)
This chart illustrates how Allied Biotech Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Allied Biotech Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Allied Biotech Corporation's total assets of NT$2.30 Billion consist of 73.7% current assets and 26.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 43.4% |
| Accounts Receivable | NT$132.99 Million | 5.9% |
| Inventory | NT$527.53 Million | 23.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$8.91 Million | 0.4% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Allied Biotech Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Allied Biotech Corporation's current assets represent 73.7% of total assets in 2024, an increase from 66.3% in 2019.
- Cash Position: Cash and equivalents constituted 43.4% of total assets in 2024, up from 21.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 23.4% of total assets.
Allied Biotech Corporation Competitors by Total Assets
Key competitors of Allied Biotech Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Allied Biotech Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Allied Biotech Corporation generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Allied Biotech Corporation generates $ 4.47 in net profit.
Allied Biotech Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.61 | 1.66 | 1.72 |
| Quick Ratio | 1.14 | 1.09 | 1.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$650.33 Million | NT$ 632.62 Million | NT$ 640.16 Million |
Allied Biotech Corporation - Advanced Valuation Insights
This section examines the relationship between Allied Biotech Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.87 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 8.6% |
| Total Assets | NT$2.26 Billion |
| Market Capitalization | $47.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Allied Biotech Corporation's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Allied Biotech Corporation's assets grew by 8.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Allied Biotech Corporation (2019–2024)
The table below shows the annual total assets of Allied Biotech Corporation from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.26 Billion | +8.56% |
| 2023-12-31 | NT$2.08 Billion | -4.77% |
| 2022-12-31 | NT$2.18 Billion | -10.58% |
| 2021-12-31 | NT$2.44 Billion | +8.00% |
| 2020-12-31 | NT$2.26 Billion | +16.09% |
| 2019-12-31 | NT$1.95 Billion | -- |